<DOC>
	<DOCNO>NCT00297921</DOCNO>
	<brief_summary>Prospective , nonrandomized , noncomparative , open-label , multicenter , 2-stage clinical study design determine overall response ( combined complete remission , complete remission incomplete blood count recovery , partial remission , blast response ) rate follow tandutinib therapy 2 group patient newly diagnose Acute Myelogenous Luekemia .</brief_summary>
	<brief_title>A Phase 2 Study Tandutinib Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For Who Decline Treatment With Standard Induction Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Male female , least 18 year age Unequivocal histologic cytologic diagnosis AML ( base WorldHealth Organization [ WHO ] and/or FAB classification ) , exclude acute promyelocytic leukemia ( FAB M3 ) . AML patient history antecedent MDS MPD eligible treatment study . In opinion investigator ineligible decline treatment standard induction therapy ECOG performance status equal le 3 Ability voluntarily provide write informed consent Determination presence absence FLT3ITD mutation enrollment ascertain determination FLT3ITD mutation status require avoid exceed enrollment either patient group Presence active malignancy AML time study entry Documented suspect central nervous system leukemia involvement Known gastrointestinal disease could interfere absorption oral tandutinib Severe central nervous system , pulmonary , renal , hepatic disease relate AML Myocardial infarction within 6 month enrollment New York Heart Association ( NYHA ) Class III Class IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , ECG evidence acute ischemia active conduction system abnormalities QTc &gt; 500 millisecond ( m ) Family history congenital QTc prolongation Pretreatment laboratory test value follow : Total bilirubin &gt; 2.5 x upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) &gt; 2.5 x ULN Serum creatinine &gt; 4.0 mg/dL Known suspect infection human immunodeficiency virus Known active infection hepatitis B hepatitis C Known suspect primary muscular neuromuscular disease ( eg , muscular dystrophy myasthenia gravis ) Receipt prior antineoplastic therapy leukemia , except prior therapy follow allow : Leukapheresis Treatment hyperleukocytosis hydroxyurea Receipt prior antineoplastic therapy MDS , except prior therapy follow allow : Growth factor/cytokine support Lenalidomide ( Revlimid™ ) Thalidomide ( Thalomid® ) Azacitidine ( Vidaza® ) Decitabine ( Dacogen ) Receipt prior antineoplastic therapy MPD , except prior therapy follow allow : Interferon alpha Anagrelide ( Agrylin® ) Hydroxyurea Antineoplastic , experimental , radiation therapy within 3 week Day 1 , except hydroxyurea treatment hyperleukocytosis permit Major surgery within 2 week Day 1 Men woman childbearing potential unwilling use adequate contraception screen 30 day last dose tandutinib A woman pregnant breast feeding . Confirmation patient pregnant must establish negative serum urine Bhuman chorionic gonadotropin ( BhCG ) pregnancy test result obtain screening period . Pregnancy test require postmenopausal surgically sterilize woman . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>